Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Cancer-Associated Fibroblasts: Challenges and Opportunities

News

April 5, 2023
PRESS RELEASE: On March 21, 2023, a new editorial perspective was published in Oncotarget, entitled, “Cancer-associated fibroblasts: challenges and opportunities.” continue reading »

Impact of Cortactin in Cancer Progression

News

April 4, 2023
PRESS RELEASE: On March 21, 2023, a new editorial paper was published in Oncotarget, entitled, “Impact of cortactin in cancer progression on Wnt5a/ROR1 signaling pathway.” continue reading »

Targeting Pre-Leukemic Cells: New Hope for Preventing Childhood B-ALL

Oncotarget

March 31, 2023
Researchers from Universidad Autónoma de Madrid published a new editorial in Oncotarget detailing a proof-of-principle experiment to prevent B-cell acute lymphoblastic leukemia (B-ALL). continue reading »

Downregulation of Angulin-1/LSR Induces Malignancy in Lung Adenocarcinoma

News

March 29, 2023
PRESS RELEASE: On March 24, 2023, a new research paper was published in Oncotarget, entitled, “Downregulation of angulin-1/LSR induces malignancy via upregulation of EGF-dependent claudin-2 and TGF-β-dependent cell metabolism in human lung adenocarcinoma A549 cells.” continue reading »

Oncotarget | Polyisoprenylated Cysteinyl Amide Inhibitors Deplete G-Proteins in Cancer Cells

News

March 28, 2023
PRESS RELEASE: On March 24, 2023, a new research paper was published in Oncotarget, entitled, “Polyisoprenylated cysteinyl amide inhibitors deplete singly polyisoprenylated monomeric G-proteins in lung and breast cancer cell lines.” continue reading »